Becton Dickinson (BD) and its subsidiary CareFusion have escalated a Class I voluntary recall for the BD Alaris Pump Module model 8100, issuing a second „Urgent Medical Device Recall (Correction)“ letter that adds 15 more affected infusion sets, updated corrective actions, and enhanced risk warnings. The U.S. Food and Drug Administration (FDA) has flagged this as the most serious recall type, citing potential for serious injury or death due to inaccurate medication delivery. As of June 11, 2025, no serious injuries or deaths have been reported, but the issue poses heightened dangers to vulnerable patients like neonates and those in critical care. 0 1 6
This update builds on the initial recall launched July 8, 2025, and expanded July 17, 2025, following internal testing that revealed performance deviations in certain infusion sets. The FDA’s Early Alert, refreshed as of September 26, 2025, emphasizes immediate actions for healthcare facilities to mitigate risks, including device removal from service and switching to compatible alternatives. 0 8
Background: A Persistent Issue in Infusion Pump Reliability
The BD Alaris System with Guardrails Suite MX is a widely used modular infusion pump for delivering fluids and medications via intravenous, intra-arterial, subcutaneous, epidural, or irrigation routes to adult, pediatric, and neonatal patients. Designed for precision in critical care settings, it relies on compatible infusion sets to ensure accurate dosing. However, design flaws in specific sets—such as in-line filters and tubing components—can lead to flow rate inaccuracies, boluses, or alarms that deviate from user manual specifications. 0 6 8
This recall is part of the FDA’s Communications Pilot to Enhance the Medical Device Recall Program, aimed at speeding up notifications and responses. It echoes prior Alaris issues, including a 2019 recall for occlusion problems and a 2025 bezel kit recall for free-flow risks, highlighting ongoing challenges in pump durability and compatibility. 3 9 The affected products were distributed nationwide in the U.S. (including Guam and Puerto Rico), as well as Canada, Belgium, and South Africa, impacting thousands of healthcare providers. 0 6
Recall Details: Expanded Scope and Performance Deviations
The recall targets the BD Alaris Pump Module model 8100 paired with a growing list of compatible infusion sets, now totaling dozens following the September 11, 2025, customer update. Key additions include 15 discontinued sets, bringing the focus to design elements like 0.2-micron filters that may cause:
- Over-infusion or under-infusion: Up to 20% deviation from set rates, risking overdose or inadequate dosing.
- Excessive post-occlusion bolus volume (POBV): Boluses exceeding 0.5 mL, potentially delivering unintended medication surges.
- Delayed alarms: Time to alarm up to 10 minutes longer than specified, delaying clinician intervention.
- Free-flow risks: In rare cases, uncontrolled delivery if tubing kinks or collapses outside the pump.
These issues stem from variations in tubing wall thickness and in-line components, identified through BD’s internal worst-case testing. While no field complaints have been received, the FDA classifies this as Class I due to the potential for life-threatening events in high-stakes environments like ICUs. 0 1 6
User manuals prior to version 12.3 may describe performance differently based on outdated testing standards, adding confusion for older systems. 8 The recall does not affect pumps manufactured after June 2017 or newer models like the BD Alaris PCU.
Corrective Actions and Recommendations
BD’s updated letter, sent September 11, 2025, outlines immediate steps:
- Inspect and quarantine: Facilities must check inventory for affected sets (listed on BD’s recall portal) and remove them from use.
- Switch to alternatives: Use recommended compatible sets without filters or in-line components when clinically viable; BD provides a substitution guide.
- Operational checks: For 0.2-micron filter sets still in use, ensure clamps are open, tubing is kink-free, and drip chambers flow properly. Adhere strictly to manual guidelines on rate accuracy and POBV.
- Return and support: Contact BD for free replacements or repairs. U.S. customers can reach Alaris Medical Affairs at alarismedicalaffairs@bd.com or Technical Support at DL-US-INF-TechSupport@bd.com / 1-888-812-3229. Global support: 1-888-562-6018.
- Reporting: Adverse events to BD’s Complaint Center (1-844-823-5433 or productcomplaints@bd.com) and FDA’s MedWatch program.
The FDA urges immediate compliance, noting this involves physical removal from clinical and sales settings. 0 6 8
Health and Safety Implications
Inaccurate infusions can lead to catastrophic outcomes: medication errors causing organ failure, sepsis, or cardiac arrest, especially in neonates or ICU patients where dosing precision is paramount. This recall underscores broader concerns in medical device reliability, with prior Alaris issues linked to injuries and deaths from free-flow or occlusion failures. 3 5 Healthcare systems face operational disruptions, potential liabilities, and eroded trust in automated delivery tools, which handle millions of infusions annually.
Conclusions and Broader Impact
BD’s proactive expansion reflects a commitment to patient safety, but it highlights the need for rigorous post-market surveillance in infusion technology. The FDA’s pilot program has accelerated communications, potentially averting harm. As BD rolls out replacements, facilities must prioritize training on manual checks to bridge gaps.
This incident may prompt regulatory scrutiny on legacy devices, urging manufacturers to accelerate upgrades. For now, swift action could prevent the first reported adverse event.
Public and Professional Relevance
Hospitals, clinics, and home care providers using Alaris systems should audit stocks immediately—delays could endanger lives. This recall serves as a reminder: Even „compatible“ components demand vigilance in high-risk care.
Contact for Further Information:
BD Alaris Medical Affairs: alarismedicalaffairs@bd.com
BD Technical Support: 1-888-812-3229
FDA MedWatch: 1-800-FDA-1088 or www.fda.gov/medwatch
Sources:
- FDA Early Alert: Infusion Set Performance Issue from BD (Updated September 26, 2025). 8
- BD Update on Voluntary Recall (September 12, 2025). 0 6
- JAMA Surgery and related publications for contextual device risks (cross-referenced via FDA database). 2 4
